Literature DB >> 17384331

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes.

David A Morrow1, Christopher P Cannon, Robert L Jesse, L Kristin Newby, Jan Ravkilde, Alan B Storrow, Alan H B Wu, Robert H Christenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17384331     DOI： 10.1161/CIRCULATIONAHA.107.182882

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  95 in total

1.  Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy.

Authors:  Sean P Collins; Christopher J Lindsell; Alan B Storrow; Gregory J Fermann; Phillip D Levy; Peter S Pang; Neal Weintraub; W Frank Peacock; Douglas B Sawyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  Troponin-keep up or be left behind.

Authors:  Aw Tar Choon
Journal:  Malays J Med Sci       Date:  2010-10

Review 3.  Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise?

Authors:  Thijs M H Eijsvogels; Antonio B Fernandez; Paul D Thompson
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

4.  Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.

Authors:  Benjamin M Scirica; Marc S Sabatine; Petr Jarolim; Sabina A Murphy; James L de Lemos; Eugene Braunwald; David A Morrow
Journal:  Eur Heart J       Date:  2010-12-22       Impact factor: 29.983

5.  High-sensitivity C-reactive protein predicts adverse cardiovascular events in patients with Takayasu arteritis with coronary artery involvement.

Authors:  X Wang; A Dang; N Lv; Q Liu; B Chen
Journal:  Clin Rheumatol       Date:  2015-02-10       Impact factor: 2.980

6.  Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.

Authors:  Shahram Shahangian; Todd D Alspach; J Rex Astles; Ajay Yesupriya; William K Dettwyler
Journal:  Arch Pathol Lab Med       Date:  2013-06-05       Impact factor: 5.534

Review 7.  Inflammatory biomarkers and coronary heart disease: from bench to bedside and back.

Authors:  Gina Biasillo; Milena Leo; Roberta Della Bona; Luigi Marzio Biasucci
Journal:  Intern Emerg Med       Date:  2010-02-25       Impact factor: 3.397

Review 8.  Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review.

Authors:  Christopher Layfield; John Rose; Aaron Alford; Susan R Snyder; Fred S Apple; Farah M Chowdhury; Michael C Kontos; L Kristin Newby; Alan B Storrow; Milenko Tanasijevic; Elizabeth Leibach; Edward B Liebow; Robert H Christenson
Journal:  Clin Biochem       Date:  2015-02-07       Impact factor: 3.281

Review 9.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White
Journal:  Nat Rev Cardiol       Date:  2012-08-25       Impact factor: 32.419

10.  Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting.

Authors:  Dimas T Ikeoka; Carolina Z Vieira; Pedro A Lemos; Tania V Strabelli; Expedito E Ribeiro da Silva; Marco A Perin; Andrea Groselj-Strele; Beate Tiran; Andreas Tiran; Bruno Caramelli
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.